Pharmaceutical And Life Sciences Real World Evidence Market Report 2026

Pharmaceutical And Life Sciences Real World Evidence Market Overview

• Pharmaceutical And Life Sciences Real World Evidence market size has reached to $3.2 billion in 2025 • Expected to grow to $5.6 billion in 2030 at a compound annual growth rate (CAGR) of 11.9% • Growth Driver: Rising Demand For Personalized Medicine Driving The Market Growth Due To Advances In Genomic Technologies And Increasing Approval Of Targeted Therapies • Market Trend: Innovative Approaches In Real-World Evidence For Optimizing Drug Development And Patient Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pharmaceutical And Life Sciences Real World Evidence Market?

Pharmaceutical and life sciences real-world evidence (RWE) refers to clinical insights on the safety, effectiveness, and outcomes of drugs or therapies derived from real-world data collected outside traditional clinical trials. This data includes sources such as electronic health records, insurance claims, patient registries, and routine clinical practice, enabling evidence-based decision-making in drug development and patient care. The main components of pharmaceutical and life sciences real world evidence include services, software, and data sets. Services refer to offerings that help design, collect, analyze, and interpret real-world evidence to support clinical, regulatory, and commercial decision-making. They are classified by evidence into descriptive studies, analytical studies, and patient-reported outcomes and they leverage real-world data sources such as medical claims, clinical trials, clinical settings, patient-powered data, and other real-world data sources. They find application in drug discovery and development support, regulatory submission and label expansion, market access and reimbursement strategy, drug safety and pharmacovigilance monitoring, treatment decision support and clinical optimization, and comparative effectiveness and outcomes research, serving end users including pharmaceutical and biopharmaceutical companies, healthcare payers and providers, medical technology companies, regulatory and health technology assessment bodies, and contract research organizations and academic research institutions.

What Is The Pharmaceutical And Life Sciences Real World Evidence Market Growth Forecast?

The pharmaceutical and life sciences real world evidence market size is expected to see rapid growth in the next few years. It will grow to $5.6 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to integration of ai-driven analytics, expansion of rwe platforms and dashboards, adoption of predictive modeling tools, increasing collaboration between payers and pharma, growth of real-world evidence in personalized medicine. Major trends in the forecast period include integration of real-world data sources, predictive modeling for drug outcomes, patient-centric evidence generation, regulatory compliance optimization, advanced analytics for market access.

Global Pharmaceutical And Life Sciences Real World Evidence Market Segmentation

1) By Component: Services, Software, Data Sets 2) By Evidence: Descriptive Studies, Analytical Studies, Patient-Reported Outcomes 3) By Real-World Data Sources: Medical Claims, Clinical Trials, Clinical Setting, Patient Powered, Other Real-World Data Sources 4) By Application: Drug Discovery And Development Support, Regulatory Submission And Label Expansion, Market Access And Reimbursement Strategy, Drug Safety And Pharmacovigilance Monitoring, Treatment Decision Support And Clinical Optimization, Comparative Effectiveness And Outcomes Research 5) By End-User: Pharmaceutical And Biopharmaceutical Companies, Healthcare Payers And Providers, Medical Technology Companies, Regulatory And Health Technology Assessment Bodies, Contract Research Organizations And Academic Research Institutions Subsegments: 1) By Services: Consulting Services, Regulatory Services Or Support, Data Management Services Or Data Integration 2) By Software: RWE Platforms And Dashboards, Predictive Modeling Or Analytics Tools 3) By Data Sets: Electronic Health Records, Patient Registries, Claims And Billing Data

What Is The Driver Of The Pharmaceutical And Life Sciences Real World Evidence Market?

The growing demand for personalized medicine is expected to propel the growth of the pharmaceutical and life sciences real-world evidence market going forward. Personalized medicine is an approach that customizes healthcare and therapies based on a patient’s unique biological and personal characteristics. The use of personalized medicine is increasing due to advances in genomic technologies, which allow healthcare providers to analyze a patient’s genetic information quickly and accurately, enabling more targeted and effective treatments. Real-world evidence in pharmaceutical and life sciences enables personalized medicine by analyzing real patient data to identify which treatments are most effective and safe for specific patient subgroups. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the growing demand for personalized medicine is driving the growth of the pharmaceutical and life sciences real-world evidence market.

Key Players In The Global Pharmaceutical And Life Sciences Real World Evidence Market

Major companies operating in the pharmaceutical and life sciences real world evidence market are UnitedHealth Group Incorporated, Oracle Corporation, IQVIA Holdings Inc., ICON plc, Parexel International Corporation, Cegedim SA, Veradigm Inc., Tempus AI Inc., Saama Technologies LLC, Komodo Health Inc., Owkin Inc., Trinity Life Sciences LLC, TriNetX LLC, OM1 Inc., HealthVerity Inc., Claritas Rx Inc., PurpleLab Inc., Atropos Health PBC, EvidentIQ Group GmbH, CuriMeta Inc., Medaffcon Oy, and Mahalo Health Inc.

Global Pharmaceutical And Life Sciences Real World Evidence Market Trends and Insights

Major companies operating in the pharmaceutical and life sciences real-world evidence market are concentrating on developing integrated data-driven platforms to enhance clinical trial efficiency, improve patient engagement, and support regulatory and health economics submissions. Integrated data-driven platforms combine diverse real-world data sources, including patient-reported outcomes and wearable device data, into structured modules that streamline recruitment, screening, enrollment, and ongoing patient interaction. For instance, in September 2023, Maxis Clinical Sciences, a US-based boutique consulting firm, introduced a comprehensive real-world evidence solution designed to support patient-focused clinical research and drug development. The platform integrates multiple data streams into pre-configured operational modules, enabling faster trial execution while facilitating regulatory approvals, health economics and outcomes research (HEOR), and drug repurposing strategies.

What Are Latest Mergers And Acquisitions In The Pharmaceutical And Life Sciences Real World Evidence Market?

In July 2025, Datavant Inc., a US-based healthcare data connectivity and analytics company, acquired Aetion Inc. for an undisclosed amount. Through this acquisition, Datavant Inc. aims to enhance its real-world evidence and analytics platform by integrating Aetion Inc.’s advanced real-world data analysis capabilities, enabling more robust insights for healthcare decision-making and streamlined data-driven research. Aetion Inc. is a US-based health technology company specializing in real-world evidence generation and analytics solutions for healthcare and life sciences.

Regional Insights

North America was the largest region in the pharmaceutical and life sciences real world evidence market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pharmaceutical And Life Sciences Real World Evidence Market?

The pharmaceutical and life sciences real-world evidence market consists of revenues earned by entities by providing services such as observational study design, data collection and management, and real-world data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Pharmaceutical And Life Sciences Real World Evidence Market Report 2026?

The pharmaceutical and life sciences real world evidence market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical and life sciences real world evidence industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.